ADPKD is the most common inherited renal disorder worldwide, impacting approximately 1 in every 500 Canadians. An estimated 45% to 70% of patients with ADPKD progress to end-stage renal disease by age 65 years.
Are you ready to take on the challenge? Help spread the word about PKD Awareness Day and what it's like to live with polycystic kidney disease! Record a short video with your smartphone and tell us your story...
Check out these 10 simple ways you can support your favourite nonprofits. They take less than five minutes and come at no cost!
In 2016, an Ontario family impacted by PKD for generations got together with their friends to bike the Bruce Trail in an effort to raise money for PKD research. They travelled 480 km and raised over $11,000. This year, Bike to the Moon participants across Canada travelled over 4,000 km...
Each year, Health Canada recognizes September 4th as National PKD Awareness Day! This year we are looking for volunteers who want to help spread awareness in their own communities by working with us to secure local proclamations.
Join us for the 2018 Walk to END PKD, the PKD Foundation of Canada's signature fundraising campaign!
On Monday, April 9, the PKD Foundation of Canada attended the Can-SOLVE CKD SPOR Initiative reception where we were awarded the Pewter Upper Canada Medal by the Toronto General & Western Hospital Foundation for our support of Dr. York Pei’s Hereditary Kidney Disease Clinic at Toronto General Hospital.
We wish to share this prestigious honour with every volunteer and donor who has joined in the fight to end PKD, furthered our mission and helped to advance critical Canadian research of PKD.
History of the medal: The Upper Canada Medal was originally created by the Loyal and Patriotic Society of Upper Canada to provide recognition of distinguished service and bravery to volunteer soldiers in the War of 1812.
Recognizing an even greater need, the Loyal and Patriotic Society decided to reduce the medals to gold bullion for the establishment, in 1829, of the original Toronto General Hospital.
Toronto General & Western Hospital Foundations continue to honour both the original intent of the medals - to recognize distinguished service - and their later role - to support the greater good.
Many thanks to the Toronto General & Western Hospital Foundation for this recognition.
The FDA Approves JYNARQUE™ as the First Treatment in the United States for Adult Patients with ADPKD
We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).
Hi, my name is Graham Scoles and I became aware of the PKD Foundation of Canada in 2015. I looked into starting a PKD chapter in Saskatoon at that time and we are slowly growing. I was diagnosed with PKD in 1986 and started dialysis in 1992. I was fortunate to receive a cadaveric kidney in 1994, which performed well until about 2017. A year later, I am now back on dialysis and hoping to receive a second transplant.
As a PKD patient on dialysis, it is exciting to see some of the advances that are being made in both understanding and treating PKD, in transplantation and also in kidney disease in general. This research is of course possible in part through funds raised by the PKD Foundation of Canada and its chapters.
Our Saskatoon Chapter is still small but through our meetings we hope to provide an opportunity for those affected by PKD in and around the city to come together for friendship and discussion.